Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CANCER-SPECIFIC TRANS-SPLICING RIBOZYME AS GENE THERAPY PRODUCT COMBINED WITH RADIOTHERAPY
Document Type and Number:
WIPO Patent Application WO/2023/014206
Kind Code:
A1
Abstract:
The present invention relates to a cancer-specific trans-splicing ribozyme as a gene therapy product combined with radiotherapy. The ribozyme of the present invention is safe because of the cancer tissue-specific expression thereof and exhibits a high expression efficiency at a post-transcriptional level and thus can be provided as a safe and effective gene therapy product. When administered after radiotherapy, the ribozyme exhibits high anticancer effects even at a low dose of radiation and a low dose of gene therapy product and thus is expected to be used in a cancer therapy method and a radiation-resistant cancer therapy method with no or little adverse effects.

Inventors:
LEE SEONG-WOOK (KR)
HAN SEUNG RYUL (KR)
PARK HEE CHUL (KR)
CHOI CHANGHOON (KR)
SHIN SUNGWON (KR)
Application Number:
PCT/KR2022/011774
Publication Date:
February 09, 2023
Filing Date:
August 08, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
RZNOMICS INC (KR)
International Classes:
A61K48/00; A61K31/7105; A61P35/00; C12N15/113
Domestic Patent References:
WO2015194853A12015-12-23
Foreign References:
KR20200102943A2020-09-01
KR20190007488A2019-01-22
KR20160038674A2016-04-07
KR102195221B12020-12-24
KR20160038674A2016-04-07
Other References:
"Final report", 26 January 2018, DANKOOK UNIVERSITY, Korea, article LEE SEONGWOOK: "Development of self-regulation targeting gene therapy technology after gene transcription and transcription", pages: 1 - 154, XP093032293
Attorney, Agent or Firm:
MUHANN PATENT & LAW FIRM (KR)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: COVER OF ELECTRONIC DEVICE

Next Patent: METHOD AND DEVICE FOR SUPPORTING POWER SAVING IN WIRELESS COMMUNICATION SYSTEM